PROPHYLACTIC PLATELET DOSE STRATEGY TO PREVENT BLEEDING IN THROMBOCYTOPENIA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As platelet use continues to increase at a rate disproportionately higher than that of red blood cells, it is important to identify the most cost-effective strategies for providing platelet support. Identification and implementation of the most safe and cost effective strategies for providing platelet support is crucial for effective disease management without depleting platelet supplies. The primary objective of this study is to compare the three study arms of high, medium, and lower dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding, as determined by the Platelet Dose Trial Bleeding Scale. Secondary objectives are to compare the three study arms with respect to platelet and hemostasis related outcomes (i.e., platelet utilization rates, frequency of transfusions, days of platelet support, number of days to first Grade 2+ bleeding, highest category of bleeding during time on the study, bleeding severity, etc.). A cost analysis will also be conducted.